Literature DB >> 16968407

Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection.

V Peruhype-Magalhães1, O A Martins-Filho, A Prata, L De A Silva, A Rabello, A Teixeira-Carvalho, R M Figueiredo, S F Guimarães-Carvalho, T C A Ferrari, J Van Weyenbergh, R Correa-Oliveira.   

Abstract

Considering the complexity of the immunological events triggered during active visceral Leishmaniasis (VL), the relevance of the segregation of the immune response during human VL into type 1 and type 2 still remains unclear. For this purpose, in individuals living in risk areas for VL, we have evaluated especially asymptomatic individuals and patients with active VL, the plasmatic levels of cytokines and reactive nitrogen species under ex vivo conditions. In addition, we have also performed an analysis of intracellular cytokine patterns of circulating leucocytes after short-term culture, particularly in the absence of antigenic-specific stimulation, in order to reflect dynamic events of immune response in vivo during Leishmania chagasi infection. Although asymptomatic individuals and non-infected subjects presented a similar immunological profile, an outstanding inflammatory/regulatory profile, based on higher plasmatic levels of cytokines such as interleukin (IL)-8, interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha, IL-6 and IL-10, was associated with clinical status observed in active VL. In this context, we hypothesize that IL-10, through its ability to inhibit anti-leishmanial macrophage activation, associated with the lower frequency of TNF-alpha(+) monocytes and ordinary levels of nitrite and nitrate are the major mechanisms associated with disease onset.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968407      PMCID: PMC1809731          DOI: 10.1111/j.1365-2249.2006.03171.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

Review 1.  Chemokines in host-protozoan-parasite interactions.

Authors:  M P Brenier-Pinchart; H Pelloux; D Derouich-Guergour; P Ambroise-Thomas
Journal:  Trends Parasitol       Date:  2001-06

2.  Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome.

Authors:  V Peruhype-Magalhães; O A Martins-Filho; A Prata; L de A Silva; A Rabello; A Teixeira-Carvalho; R M Figueiredo; S F Guimarães-Carvalho; T C A Ferrari; R Correa-Oliveira
Journal:  Scand J Immunol       Date:  2005-11       Impact factor: 3.487

3.  Role of CD8+ T cells in endogenous interleukin-10 secretion associated with visceral leishmaniasis.

Authors:  B J Holaday
Journal:  Mem Inst Oswaldo Cruz       Date:  2000 Mar-Apr       Impact factor: 2.743

4.  Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events.

Authors:  S Bhattacharyya; S Ghosh; P L Jhonson; S K Bhattacharya; S Majumdar
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 5.  T-cell response in human leishmaniasis.

Authors:  A Kharazmi; K Kemp; A Ismail; S Gasim; A Gaafar; J A Kurtzhals; A M El Hassan; T G Theander; M Kemp
Journal:  Immunol Lett       Date:  1999-01       Impact factor: 3.685

6.  Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis.

Authors:  E M Carvalho; O Bacellar; C Brownell; T Regis; R L Coffman; S G Reed
Journal:  J Immunol       Date:  1994-06-15       Impact factor: 5.422

7.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections.

Authors:  H W Ghalib; M R Piuvezam; Y A Skeiky; M Siddig; F A Hashim; A M el-Hassan; D M Russo; S G Reed
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Interleukin 6 during active visceral leishmaniasis and after treatment.

Authors:  T van der Poll; E E Zijlstra; M Mevissen
Journal:  Clin Immunol Immunopathol       Date:  1995-10

9.  CD40 ligand-transduced co-stimulation of T cells in the development of helper function.

Authors:  D van Essen; H Kikutani; D Gray
Journal:  Nature       Date:  1995-12-07       Impact factor: 49.962

10.  Inhibition of the spontaneous apoptosis of neutrophil granulocytes by the intracellular parasite Leishmania major.

Authors:  Eresso Aga; Dörthe M Katschinski; Ger van Zandbergen; Helmut Laufs; Birgit Hansen; Kerstin Müller; Werner Solbach; Tamás Laskay
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

View more
  55 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Let off the leash: kala-azar following the use of tumour necrosis factor antibodies.

Authors:  Anjum Khan; Gerald Coakley; Catherine Cosgrove; Diana Lockwood
Journal:  BMJ Case Rep       Date:  2010-10-13

3.  Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood.

Authors:  Om Prakash Singh; Kamlesh Gidwani; Rajiv Kumar; Susanne Nylén; Stephen L Jones; Marleen Boelaert; David Sacks; Shyam Sundar
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

4.  Role of IL-21 in host pathogenesis in experimental visceral leishmaniasis.

Authors:  R Khatonier; A M Khan; P Sarmah; G U Ahmed
Journal:  J Parasit Dis       Date:  2018-08-22

5.  Chronicity of dermal leishmaniasis caused by Leishmania panamensis is associated with parasite-mediated induction of chemokine gene expression.

Authors:  Adriana Navas; Deninson Alejandro Vargas; Marina Freudzon; Diane McMahon-Pratt; Nancy Gore Saravia; María Adelaida Gómez
Journal:  Infect Immun       Date:  2014-04-21       Impact factor: 3.441

6.  High levels of CD4⁺ CTLA-4⁺ Treg cells and CCR5 density in HIV-1-infected patients with visceral leishmaniasis.

Authors:  A Vallejo; M Abad-Fernández; S Moreno; A Moreno; M J Pérez-Elías; F Dronda; J L Casado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-21       Impact factor: 3.267

7.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

8.  Evaluation of the influence of tissue parasite density on hematological and phenotypic cellular parameters of circulating leukocytes and splenocytes during ongoing canine visceral leishmaniasis.

Authors:  L L Guerra; A Teixeira-Carvalho; R C Giunchetti; O A Martins-Filho; A B Reis; R Corrêa-Oliveira
Journal:  Parasitol Res       Date:  2008-11-05       Impact factor: 2.289

9.  Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.

Authors:  Sandeep Verma; Rajesh Kumar; Gajendra Kumar Katara; Laishram Chandreshwor Singh; Narender Singh Negi; V Ramesh; Poonam Salotra
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

Review 10.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.